• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Transcend Therapeutics

Tuesday, June 04, 2024
Company Presentation
CNS/Neurological
Company Presentation Theater 1
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric disease. Transcend is developing TSND-201 (methylone), a rapid-acting neuroplastogen, as a treatment for post-traumatic stress disorder (PTSD) and other CNS indications. Transcend recently presented positive interim Phase 2a in patients with PTSD, which demonstrated rapid, robust, and durable therapeutic effects in PTSD and a signal for rapid, robust, and durable improvements in depressive symptoms. Transcend’s leadership team has made pivotal contributions to 13 successful NDAs (including recent MDD approval), $3.5B in M&A, and significant public company value creation.
Transcend Therapeutics
Company Website: https://www.transcendtherapeutics.com
Lead Product in Development: TSND-201

Company HQ City

New York

Company HQ State

NY

Company HQ Country

United States

CEO/Top Company Official

Blake Mandell

Development Phase of Primary Product

Phase II
Primary Speaker
Blake Mandell, BA
CEO
Transcend Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS